Clinical trials: Dermatitis, open to volunteers
Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).
- Conditions
- Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis, Atopic Dermatitis (AD)
- Trial name
- CLEAR-AD1 (NCT06855745)
- Testing
- zabalafin
- Where
- 12 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Alphyn Biologics
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 40 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Atopic Eczema
A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.
- Trial name
- NCT06453512
- Testing
- Doublebase Once
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- Dermal Laboratories Ltd
Atopic Dermatitis (AD)
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
- Trial name
- NCT07544862
- Testing
- Stapokibart
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
Lichen Simplex Chronicus
A Study to Evaluate the Multiple Dose Ascending of PG-033 in Healthy Adult Participants.
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles of multiple ascending oral doses(MAD) of PG-033 by directly comparing it with placebo.
- Trial name
- NCT07619183
- Testing
- PG-033 tablets
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Atopic Dermatitis
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
This is a first-in-human (FIH) study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of GLR2053 in healthy male and female adult participants, and to evaluate the effect of a…
- Trial name
- NCT07920783
- Testing
- GLR2053 Tablets
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Atopic Dermatitis, Eczema, Atopic
Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.
Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group. 5 visits: inclusion visit [day (D) 0] and 4 follow-up visits (D30, D60, D90, and D120).
- Trial name
- NCT05575882
- Testing
- Skin hydration, Barrier function measurement, Potential of hydrogen measurement (pH)
- Where
- 3 sites in Argentina, India and 1 more
- Volunteers
- 100 people
- Sponsor
- NAOS Argentina S.A.
Atopic Dermatitis
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06397911
- Testing
- FB825
- Where
- 16 sites in United States, Taiwan
- Volunteers
- 114 people
- Sponsor
- Oneness Biotech Co., Ltd.
Health Adult Subjects, Moderate-to-Severe Atopic Dermatitis
A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN5003 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07801612
- Testing
- HXN5003
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Atopic Dermatitis
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
It is a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial to evaluate the efficacy of QLM3003 ointment at week 8 based on the primary endpoint (EASI 75) and key secondary endpoint…
- Trial name
- NCT06880276
- Testing
- 1.5% QLM3003 ointment, 2% QLM3003 ointment
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Clinical Study of HRS-8797 in Healthy Participants
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.
- Trial name
- NCT07698756
- Testing
- HRS-8797
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Atopic Dermatitis
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.
- Trial name
- 611 (NCT07042113)
- Testing
- new formulations of 611, existing formulations of 611
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase Ⅲ comparative study to evaluate the efficacy and safety of QL2108 to Dupixent® in adult subjects with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06884891
- Testing
- QL2108 injection, Dupixent®
- Volunteers
- 520 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study…
- Trial name
- NCT07003425
- Testing
- APG777
- Where
- 80 sites in United States, Canada and 7 more
- Volunteers
- 350 people
- Sponsor
- Apogee Therapeutics, Inc.
Microbiota, Gut Microbiome
Flourish: Exploring the Early Infant Gut Microbiome
The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months…
- Conditions
- Microbiota, Gut Microbiome, Eczema, Microbiome
- Trial name
- NCT07333482
- Testing
- Tailored Recommendations, Consult Call, Educational Email Series
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Seeding Inc
Atopic Dermatitis
A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile.
- Trial name
- AD-BEASCUITS (NCT06192563)
- Testing
- Dupilumab
- Where
- 9 sites in Italy
- Volunteers
- 230 people
- Sponsor
- Sanofi
Adolescents With Moderate-to-severe Atopic Dermatitis
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07309055
- Testing
- SHR-1819 Injection
- Where
- 2 sites in China
- Volunteers
- 201 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Seborrheic Dermatitis
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
- Trial name
- NCT07683806
- Testing
- Roflumilast Foam 0.3%, Vehicle foam
- Where
- 52 sites in China
- Volunteers
- 309 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Atopic Dermatitis
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis
- Trial name
- NCT06775860
- Testing
- ICP-332 Tablets
- Where
- 62 sites in China
- Volunteers
- 552 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Pregnancy Related, Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
- Trial name
- NCT06627335
- Testing
- Ruxolitinib Cream, TCS
- Where
- United States
- Volunteers
- 5,621 people
- Sponsor
- Incyte Corporation